Dashboard
Manage Tickers

IDYA


   

CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

guggenheim-initiates-coverage-on-ideaya-biosciences-with-buy-rating-announces-price-target-of-50
Guggenheim Initiates Coverage On IDEAYA Bi...
09/18/2025 13:00:12

Guggenheim analyst Paul Jeng initiates coverage on IDEAYA Biosciences (NASDAQ:IDYA) with a Buy rating and announces Price Ta...

buying-ideaya-might-be-the-wrong-idya-right-now
Buying IDEAYA Might Be The Wrong IDYA Righ...
09/16/2025 11:01:43

IDEAYA Stock's Adhishthana.com cycle signals prolonged weakness after a failed Cakra, with underperformance likely until Ma...

mizuho-maintains-outperform-on-ideaya-biosciences-raises-price-target-to-44
Mizuho Maintains Outperform on IDEAYA Bios...
09/12/2025 14:04:16

Mizuho analyst Graig Suvannavejh maintains IDEAYA Biosciences (NASDAQ:IDYA) with a Outperform and raises the price target fr...

alibaba-to-rally-around-35-here-are-10-top-analyst-forecasts-for-tuesday
Alibaba To Rally Around 35%? Here Are 10 T...
09/09/2025 14:11:09

rbc-capital-maintains-outperform-on-ideaya-biosciences-raises-price-target-to-38
RBC Capital Maintains Outperform on IDEAYA...
09/09/2025 13:25:57

RBC Capital analyst Leonid Timashev maintains IDEAYA Biosciences (NASDAQ:IDYA) with a Outperform and raises the price target...

cantor-fitzgerald-reiterates-overweight-on-ideaya-biosciencesto-overweight
Cantor Fitzgerald Reiterates Overweight on...
09/09/2025 13:15:58

Cantor Fitzgerald analyst Li Watsek reiterates IDEAYA Biosciences (NASDAQ:IDYA) from Overweight to Overweight.

stephens--co-reiterates-overweight-on-ideaya-biosciences-maintains-45-price-target
Stephens & Co. Reiterates Overweight on ID...
09/09/2025 13:11:34

Stephens & Co. analyst Sudan Loganathan reiterates IDEAYA Biosciences (NASDAQ:IDYA) with a Overweight and maintains $45 ...

jmp-securities-maintains-market-outperform-on-ideaya-biosciences-raises-price-target-to-45
JMP Securities Maintains Market Outperform...
09/08/2025 14:10:24

JMP Securities analyst Silvan Tuerkcan maintains IDEAYA Biosciences (NASDAQ:IDYA) with a Market Outperform and raises the pr...

ideaya-biosciences-reports-data-from-phase-12-combination-trial-of-ide397-and-trodelvy-in-mtap-deletion-urothelial-cancer
IDEAYA Biosciences Reports Data From Phase...
09/08/2025 12:07:50

Overall response rate (ORR) of 57% (4/7; 3cPR+1uPR) in patients treated with a combination of 30 mg IDE397 plus 7.5mg/kg Trodel...

ideaya-biosciences-reports-tumor-shrinkage-and-vision-gains-in-eye-cancer-trial
IDEAYA Biosciences Reports Tumor Shrinkage...
09/08/2025 10:03:07

IDEAYA Biosciences, Inc. (NASDAQ:IDYA), a leading precision medicine oncology company, will present positive interim data at th...

ideaya-biosciences-and-hengrui-pharma-presented-initial-data-from-hengruis-phase-1-trial-of-ide849-shr-4849-at-the-iaslc-2025-world-conference-on-lung-cancer
Ideaya Biosciences And Hengrui Pharma Pres...
09/07/2025 17:21:25

80.0% (8/10) ORR and 70.0% (7/10) confirmed ORR in 2L SCLC; a 73.7% (14/19) ORR and 57.9% (11/19) confirmed ORR (1 pending conf...

jmp-securities-initiates-coverage-on-ideaya-biosciences-with-market-outperform-rating-announces-price-target-of-41
JMP Securities Initiates Coverage On IDEAY...
09/04/2025 12:33:54

JMP Securities analyst Silvan Tuerkcan initiates coverage on IDEAYA Biosciences (NASDAQ:IDYA) with a Market Outperform ratin...

barclays-initiates-coverage-on-ideaya-biosciences-with-overweight-rating-announces-price-target-of-40
Barclays Initiates Coverage On IDEAYA Bios...
09/04/2025 10:49:04

Barclays analyst Peter Lawson initiates coverage on IDEAYA Biosciences (NASDAQ:IDYA) with a Overweight rating and announces ...

ideaya-biosciences-enrolls-first-patient-in-phase-12-trial-of-ide397-a-potential-first-in-class-mat2a-inhibitor-and-trodelvy-in-mtap-deletion-non-small-cell-lung-cancer
Ideaya Biosciences Enrolls First Patient I...
09/04/2025 10:02:11

jp-morgan-maintains-overweight-on-ideaya-biosciences-raises-price-target-to-74
JP Morgan Maintains Overweight on IDEAYA B...
09/03/2025 14:57:39

JP Morgan analyst Anupam Rama maintains IDEAYA Biosciences (NASDAQ:IDYA) with a Overweight and raises the price target from ...

correction-ideaya-biosciences-submits-an-investigational-new-drug-application-to-fda-for-ide892-phase-1-dose-escalation-trial-of-ide892-in-mtap-deleted-lung-cancer-expected-to-start-in-q4-2025-and-combination-trials-with-ide397-in-1h-2026
CORRECTION: Ideaya Biosciences Submits An ...
09/03/2025 11:13:59

IDEAYA Biosciences, Inc. (NASDAQ:IDYA), a leading precision medicine oncology company, announced the submission of an investiga...

Core News & Articles
Market-Moving News for September 2nd
09/02/2025 11:23:26

ONC: 9% | BeOne Medicines shares are trading higher after the company last week announced topline results from a Phase 1/2 stud...

servier-and-ideaya-biosciences-announced-an-exclusive-license-agreement-for-darovasertib-for-rare-eye-cancer-servier-obtains-rights-for-darovasertib-outside-us-ideaya-will-receive-an-upfront-payment-of-210m-and-up-to-320-million-in-milestones-plus-sales-based-royalties
Servier And Ideaya Biosciences Announced A...
09/02/2025 10:05:59

Servier and IDEAYA Biosciences enter into an exclusive license agreement for regulatory and commercial rights to darovasertib o...

Core News & Articles
12 Health Care Stocks Moving In Friday's A...
08/29/2025 21:06:12

ideaya-biosciences-announces-abstract-with-data-from-single-arm-phase-12-trial-of-darovasertib-in-combination-with-crizotinib-in-first-line-mum-accepted-for-oral-presentation-at-2025-smr
IDEAYA Biosciences Announces Abstract With...
08/29/2025 18:02:11

IDEAYA Biosciences, Inc. (NASDAQ:IDYA), a leading precision medicine oncology company, today announced that an abstract with da...

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION